HC Wainwright Reaffirms “Buy” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $20.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 52.56% from the company’s previous close.

A number of other research firms have also issued reports on ENTA. Evercore ISI cut their price target on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a report on Monday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. JPMorgan Chase & Co. began coverage on Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Jefferies Financial Group upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the company from $14.00 to $20.00 in a report on Wednesday, October 1st. Finally, Westpark Capital upped their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, September 30th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.33.

Enanta Pharmaceuticals Stock Down 2.5%

NASDAQ:ENTA opened at $13.11 on Friday. The stock has a fifty day simple moving average of $13.81 and a 200 day simple moving average of $10.48. The firm has a market capitalization of $378.35 million, a price-to-earnings ratio of -3.42 and a beta of 0.95. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%.The firm had revenue of $15.13 million for the quarter, compared to the consensus estimate of $15.60 million. Equities analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Activity at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 4,743 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the transaction, the chief executive officer owned 858,026 shares in the company, valued at $12,209,709.98. The trade was a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Yat Sun Or sold 2,390 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $34,009.70. Following the completion of the transaction, the insider directly owned 371,392 shares in the company, valued at approximately $5,284,908.16. The trade was a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 11,961 shares of company stock valued at $170,149. Insiders own 13.89% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 5.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock worth $720,000 after purchasing an additional 6,549 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,779 shares during the last quarter. CWM LLC boosted its holdings in Enanta Pharmaceuticals by 22.1% in the second quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 3,879 shares in the last quarter. Bank of Montreal Can increased its position in Enanta Pharmaceuticals by 32.8% during the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock worth $256,000 after buying an additional 8,365 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in Enanta Pharmaceuticals by 2.1% during the first quarter. Acadian Asset Management LLC now owns 867,037 shares of the biotechnology company’s stock worth $4,782,000 after buying an additional 17,613 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.